Biodesix, Inc., has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. The program is designed to help all businesses in the U.S. and incorporates two highly-accurate diagnostic tests for COVID-19 with an end-to-end customized solution to assist companies in their goals of preventing and slowing the spread of COVID-19 while resuming business operations.

Results for both tests are provided in 24 hours after the sample is received at the Biodesix Laboratory.

Biodesix has commercialized two tests developed by Bio-Rad Laboratories, Inc. for COVID-19 detection: the SARS-CoV-2 ddPCR Test (molecular) and the Platelia SARS-CoV-2 Total Ab Test (antibody).

The molecular test diagnoses active COVID-19 infection with high accuracy and uses a nasopharyngeal swab to collect the sample. The molecular test can be used to identify patients who should quarantine and should not yet return to work.

The antibody test identifies patients who may have previously been infected by COVID-19. When tested more than eight days following the onset of symptoms, the test achieves 97.50% sensitivity and 99.56% specificity using a simple blood draw.

This test identifies patients who may have developed some level of immunity against the virus.